Announcements Trials
Browse Landscape

Status

No longer available 3Temporarily not available 1Approved for marketing 1

Sponsor Class

OTHER 2NIH 1

Study Type

Expanded_access 3

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Dermatologic 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Melanoma 1Leukemia 1Immunoproliferative Disorders 1Immune System Diseases 1

Interventions

trametinib 4nilotinib 4elotuzumab 4dabrafenib 4Amifampridine 4regorafenib 3pembrolizumab 3midostaurin 3fludarabine phosphate 3fludarabine 3Nivolumab 3Lenalidomide 3Ipilimumab 3Everolimus 3Dexamethasone 3Cyclophosphamide 3Crizotinib 3Bortezomib 3Axitinib 3venetoclax 2veliparib 2tazemetostat 2talimogene laherparepvec 2navitoclax 2gallium 68 PSMA-11 2ceritinib 2carbon-11 acetate 2aldesleukin 2Whole-Body Irradiation 2Trabectedin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
No longer available × Expanded_access × Cyclophosphamide × Clear all
NCT03594162 2021-12-03

Compassionate Use of CAR T Cells Targeting the CD19 Antigen and Containing the Inducible Caspase 9 Safety Switch

UNC Lineberger Comprehensive Cancer Center

No longer available
LymphoidOther hematologic neoplasm

Immune System Diseases, Immunoproliferative Disorders, Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04135092 2020-09-04

Single Patient Protocol: A Phase II Study Using the Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated Neoantigens in a Patient With Metastatic Cancer Plus the Administration of Pembrolizumab

National Institutes of Health Clinical Center (CC)

No longer available
NCT01005537 2010-08-06

Cyclophosphamide, Autologous Lymphocytes, and Aldesleukin in Treating Patients With Metastatic Melanoma

Fred Hutchinson Cancer Center

No longer available
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡